China Fast Becoming World’s Pharmaceutical Formulation Factory
This article was originally published in PharmAsia News
Executive Summary
Zhejiang Huahai Pharmaceutical will cooperate with U.S. firm Enspire and invest $10 million to set up a new overseas company to develop, produce and sell soft capsules. Last July, Huahai gained U.S. FDA tentative approval to launch its anti-AIDS drug nevirapine in the U.S. in 2012, a first for a pharmaceutical company from China. In addition, it is China's only enterprise to receive FDA authorization for its solid pharmaceutical formulation workshop. Experts observe that currently fewer than 10 pharmaceutical firms in China have gained European and American certification. More than 20 companies are in the application stage and may receive licenses over the next two years. China's low-cost advantage attracts outsourcing by pharmaceutical MNCs and the country is poised to be the world's pharmaceutical formulation factory
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.